Get started
Author

Robert A. Mullinax

An inhibitor of oxidative phosphorylation exploits cancer vulnerability
2018 · Jennifer R. Molina, Yuting Sun, et al. · Nature Medicine · 924
Subgroup of Reproductive Functions of Progesterone Mediated by Progesterone Receptor-B Isoform
2000 · Biserka Mulac-Jericevic, Robert A. Mullinax, et al. · Science · 704
Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer
2018 · Yonathan Lissanu Deribe, Yuting Sun, et al. · Nature Medicine · 268
Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib
2020 · Yuting Sun, Brooke A. Meyers, et al. · Cancer Research · 103
Discovery of IPN60090, a Clinical Stage Selective Glutaminase‑1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties
2020 · Michael J. Soth, Kang Le, et al. · Journal of Medicinal Chemistry · 94
Regulators of the Proteasome Pathway, Uch37 and Rpn13, Play Distinct Roles in Mouse Development
2010 · Amin Al-Shami, Kanchan G. Jhaver, et al. · PLoS ONE · 87
PDF
Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation
2019 · Yuting Sun, Madhavi Bandi, et al. · Cell Reports · 59
PDF
Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer
2021 · Akira Inoue, Frederick S. Robinson, et al. · Gastroenterology · 40
Author Correction: Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer
2018 · Yonathan Lissanu Deribe, Yuting Sun, et al. · Nature Medicine · 24
Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R
2020 · Barbara Czako, Joseph. R. Marszalek, et al. · Journal of Medicinal Chemistry · 18
Abstract 985: BI 905711 selectively induces apoptosis and anti-tumor response in TRAILR2/CDH17- expressing pancreatic cancer models
2021 · Jing Han, Annette A. Machado, et al. · Cancer Research · 1
Abstract C036: Discovery of IACS-13909, an allosteric SHP2 inhibitor that overcomes multiple mechanisms underlying osimertinib resistance
2019 · Yuting Sun, Brooke A Meyers, et al. · Molecular Cancer Therapeutics · 1
Trls-12 Pd-1 and Lag3 Combination Blockade Therapy Reduces Melanoma Brain Metastatic Tumor Growth in Preclinical Models and Is Abrogated by Neutrophil Infiltration
2025 · David Peng, Mariah Williams, et al. · Neuro-Oncology Advances
PDF
Data from Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib
2023 · Yuting Sun, Brooke A. Meyers, et al.
Data from Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib
2023 · Yuting Sun, Brooke A. Meyers, et al.
Supplementary information from Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib
2023 · Yuting Sun, Brooke A. Meyers, et al.
Supplementary information from Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib
2023 · Yuting Sun, Brooke A. Meyers, et al.
Multi-disciplinary efforts to evaluate the therapeutic potential of CDK11, a novel transcription associated cyclin dependent kinase.
2022 · Christopher L. Carroll, Jan Reiling, et al.
PDF
Abstract LB-124: Promoting an anti-tumor immune environment with a novel, exquisitely selective CSF1R inhibitor
2018 · Erika Suzuki, Jeffrey J. Kovacs, et al. · Cancer Research
Works count: 19
Citation count: 2,323
H-index: 10
I10-index: 10
Year
Topic
Type